Rybrevant Faspro
NDC 57894-510 · Janssen Biotech, Inc.
Packages
57894-510-01 — 1 VIAL, SINGLE-DOSE in 1 CARTON (57894-510-01) / 10 mL in 1 VIAL, SINGLE-DOSE
Billed under HCPCS
J9062 — Injection, amivantamab 5 mg and hyaluronidase-lpuj Medicare Part B payment limit (ASP + 6%): $40.74
Related Codes
Same active ingredient
FDA lists these products with the same active ingredient.
0003-3120 — nivolumab and hyaluronidase-nvhy, 0003-6120 — nivolumab and hyaluronidase-nvhy, 18657-117 — Hyaluronidase, 50242-077 — Trastuzumab and hyaluronidase-oysk, 50242-108 — rituximab and hyaluronidase, 50242-109 — rituximab and hyaluronidase, 50242-245 — pertuzumab, trastuzumab, and hyaluronidase-zzxf, 50242-260 — pertuzumab, trastuzumab, and hyaluronidase-zzxf, 50242-554 — ocrelizumab and hyaluronidase, 50242-933 — atezolizumab and hyaluronidase-tqjs, 51662-1555 — HYALURONIDASE, 57894-501 — amivantamab-vmjw, 57894-503 — daratumumab and hyaluronidase-fihj (human recombinant), 57894-514 — AMIVANTAMAB and HYALURONIDASE-lpuj (HUMAN RECOMBINANT), 57894-515 — AMIVANTAMAB and HYALURONIDASE-lpuj (HUMAN RECOMBINANT), 57894-522 — AMIVANTAMAB and HYALURONIDASE-lpuj (HUMAN RECOMBINANT), 73475-1221 — efgartigimod alfa and hyaluronidase (human recombinant), 73475-3102 — efgartigimod alfa and hyaluronidase (human recombinant)